FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323928951> ?p ?o ?g. }

• W4323928951 endingPage "112847" @default.
• W4323928951 startingPage "112847" @default.
• W4323928951 abstract "Vascular endothelial growth factor receptor (VEGFR)-mediated signalling contributes to andgiogenesis and therapy resistance in pancreatic ductal adenocarcinoma (PDAC). Ramucirumab (RAM) is a VEGFR2 monoclonal antibody. We conducted a randomised phase II trial to compare progression-free survival (PFS) between mFOLFIRINOX with or without RAM in first line therapy of metastatic PDAC.This phase II randomised, multi-centre, placebo controlled, double-blinded, trial randomly assigned to recurrent/metastatic PDAC patients to either mFOLFIRINOX/RAM (Arm A) or mFOLFIRINOX/placebo (Arm B). The primary endpoint is PFS at 9 months, and the secondary endpoints include overall survival (OS), response rate and toxicity evaluation.A total of 86 subjects enrolled, 82 eligible (42 in Arm A versus 40 in Arm B). The mean age was comparable (61.7 versus 63.0, respectively). Majority were White (N = 69) and males (N = 43). The median PFS was 5.6 compared to 6.7 months, for Arm A and B, respectively. At 9 months, the PFS rates were 25.1% and 35.0% for Arms A and B, respectively (p = 0.322). The median OS in Arm A was 10.3 compared to 9.7 months for Arm B (p = 0.094). The disease response rate for Arm A was 17.7% compared to Arm B of 22.6%. FOLFIRINOX/RAM combination was well tolerated.The addition of RAM to FOLFIRINOX did not significantly impact PFS or OS. The combination was well tolerated (Funded by Eli Lilly; ClinicalTrials.gov number, NCT02581215)." @default.
• W4323928951 created "2023-03-12" @default.
• W4323928951 creator A5010925062 @default.
• W4323928951 creator A5021904320 @default.
• W4323928951 creator A5025069765 @default.
• W4323928951 creator A5039468247 @default.
• W4323928951 creator A5044831450 @default.
• W4323928951 creator A5046214153 @default.
• W4323928951 creator A5057176768 @default.
• W4323928951 creator A5064900192 @default.
• W4323928951 creator A5065431287 @default.
• W4323928951 creator A5065673894 @default.
• W4323928951 creator A5073890392 @default.
• W4323928951 date "2023-08-01" @default.
• W4323928951 modified "2023-10-18" @default.
• W4323928951 title "Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198)" @default.
• W4323928951 cites W1906510709 @default.
• W4323928951 cites W1975193398 @default.
• W4323928951 cites W1980952563 @default.
• W4323928951 cites W2007663426 @default.
• W4323928951 cites W2009337734 @default.
• W4323928951 cites W2019607817 @default.
• W4323928951 cites W2023868654 @default.
• W4323928951 cites W2050987511 @default.
• W4323928951 cites W2087906374 @default.
• W4323928951 cites W2095774695 @default.
• W4323928951 cites W2103396260 @default.
• W4323928951 cites W2108623236 @default.
• W4323928951 cites W2115898240 @default.
• W4323928951 cites W2118362228 @default.
• W4323928951 cites W2121847974 @default.
• W4323928951 cites W2128095147 @default.
• W4323928951 cites W2137508065 @default.
• W4323928951 cites W2151253787 @default.
• W4323928951 cites W2165480504 @default.
• W4323928951 cites W2172075642 @default.
• W4323928951 cites W2317504614 @default.
• W4323928951 cites W2323248054 @default.
• W4323928951 cites W2480793872 @default.
• W4323928951 cites W2801295380 @default.
• W4323928951 cites W2999417355 @default.
• W4323928951 cites W3122478037 @default.
• W4323928951 cites W3199702982 @default.
• W4323928951 doi "https://doi.org/10.1016/j.ejca.2023.02.030" @default.
• W4323928951 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37268519" @default.
• W4323928951 hasPublicationYear "2023" @default.
• W4323928951 type Work @default.
• W4323928951 citedByCount "0" @default.
• W4323928951 crossrefType "journal-article" @default.
• W4323928951 hasAuthorship W4323928951A5010925062 @default.
• W4323928951 hasAuthorship W4323928951A5021904320 @default.
• W4323928951 hasAuthorship W4323928951A5025069765 @default.
• W4323928951 hasAuthorship W4323928951A5039468247 @default.
• W4323928951 hasAuthorship W4323928951A5044831450 @default.
• W4323928951 hasAuthorship W4323928951A5046214153 @default.
• W4323928951 hasAuthorship W4323928951A5057176768 @default.
• W4323928951 hasAuthorship W4323928951A5064900192 @default.
• W4323928951 hasAuthorship W4323928951A5065431287 @default.
• W4323928951 hasAuthorship W4323928951A5065673894 @default.
• W4323928951 hasAuthorship W4323928951A5073890392 @default.
• W4323928951 hasConcept C121608353 @default.
• W4323928951 hasConcept C126322002 @default.
• W4323928951 hasConcept C141071460 @default.
• W4323928951 hasConcept C142724271 @default.
• W4323928951 hasConcept C143998085 @default.
• W4323928951 hasConcept C168563851 @default.
• W4323928951 hasConcept C203092338 @default.
• W4323928951 hasConcept C204787440 @default.
• W4323928951 hasConcept C27081682 @default.
• W4323928951 hasConcept C2776694085 @default.
• W4323928951 hasConcept C2777148230 @default.
• W4323928951 hasConcept C2779551604 @default.
• W4323928951 hasConcept C2780210213 @default.
• W4323928951 hasConcept C2780739268 @default.
• W4323928951 hasConcept C2780962732 @default.
• W4323928951 hasConcept C29730261 @default.
• W4323928951 hasConcept C31760486 @default.
• W4323928951 hasConcept C526805850 @default.
• W4323928951 hasConcept C71924100 @default.
• W4323928951 hasConcept C90924648 @default.
• W4323928951 hasConceptScore W4323928951C121608353 @default.
• W4323928951 hasConceptScore W4323928951C126322002 @default.
• W4323928951 hasConceptScore W4323928951C141071460 @default.
• W4323928951 hasConceptScore W4323928951C142724271 @default.
• W4323928951 hasConceptScore W4323928951C143998085 @default.
• W4323928951 hasConceptScore W4323928951C168563851 @default.
• W4323928951 hasConceptScore W4323928951C203092338 @default.
• W4323928951 hasConceptScore W4323928951C204787440 @default.
• W4323928951 hasConceptScore W4323928951C27081682 @default.
• W4323928951 hasConceptScore W4323928951C2776694085 @default.
• W4323928951 hasConceptScore W4323928951C2777148230 @default.
• W4323928951 hasConceptScore W4323928951C2779551604 @default.
• W4323928951 hasConceptScore W4323928951C2780210213 @default.
• W4323928951 hasConceptScore W4323928951C2780739268 @default.
• W4323928951 hasConceptScore W4323928951C2780962732 @default.
• W4323928951 hasConceptScore W4323928951C29730261 @default.
• W4323928951 hasConceptScore W4323928951C31760486 @default.
• W4323928951 hasConceptScore W4323928951C526805850 @default.

• next